Latest Breaking News On - Tropics 02 study - Page 1 : comparemela.com

The EMA's Committee for Medicinal Products for Human Use has adopted a positive opinion regarding sacituzumab govitecan-hziy monotherapy in select patients with unresectable or metastatic hormone receptor–positive, HER2-negative breast cancer.

Comunidad autonoma de catalunaUnited statesJavier cortesInternational breast cancer centerEuropean medicines agencyMedicinal productsHuman useNorth americaSacituzumab govitecanBreast cancerHr breast cancerMetastatic breast cancerCommittee for medicinal products human useTropics 02 studyGilead sciencesAntibody drug conjugate